Abstract
Lead Optimization Strategies: Future developments, threats and opportunities for big pharma, specialty pharma and biotech
The pharmaceutical industry has undergone considerable consolidation during
the last 20 years as companies attempt to maintain double-digit sales growth
and shareholder value. Strategic mergers and acquisitions have resulted in
companies revitalizing their drug pipelines to replace blockbuster drugs that
face patent expiration. In many cases, whilst mergers cause a period of less
productive transition, significant cost-savings can be reaped and overheads
reduced. However, more and more companies are resorting to streamlining their
internal programs, both pre-clinical and clinical, to improve productivity and
the cost-effectiveness of bringing drugs to the market as well as in-licensing
late-stage products and outsourcing screening programs which may be less
economical to entertain in-house.
View Cart
